The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s showing significant potential in clinical trials for treating obesity. Unlike some available weight loss solutions, retatrutide appears to deliver a significant substantial decrease in body weight and benefit metabolic mar